Benzinga · Oct 27, 2026
Cantor Fitzgerald Maintains Overweight on Nyxoah, Lowers Price Target to $3
Cantor Fitzgerald analyst Sarah James maintains Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $6 to $3.
NY
NASDAQ · NYXH
Nyxoah S.A.
Healthcare · Medical - Instruments & Supplies
$0.89
Down-$0.02 (-1.85%)
Updated Oct 30, 2026, 9:20 PM
SID Score
2.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 181.49M
- P/E ratio
- -1.85
- Dividend yield
- 0.00%
- 52-week range
- $0.80 – $3.66
- Volume
- 178.76K
- Avg. volume
- 58.93K
Price performance · NYXH
NYXH price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
NYXH closed at $0.89 after 21 trading sessions, down 33.24% for the selected period.
- Last close
- $0.89
- Period change
- -33.24%
- Period low
- $0.82
- Period high
- $1.43
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $0.9238 | $0.9304 | $0.8801 | $0.8879 | 178.76K |
| Oct 28, 2026 | $0.9456 | $0.9744 | $0.8961 | $0.90 | 587.48K |
| Oct 27, 2026 | $0.93 | $0.93 | $0.8909 | $0.9108 | 295.87K |
| Oct 26, 2026 | $0.8412 | $0.858 | $0.813 | $0.8564 | 232.4K |
| Oct 23, 2026 | $0.8627 | $0.8675 | $0.80 | $0.8344 | 181.01K |
| Oct 22, 2026 | $0.85 | $0.8619 | $0.8011 | $0.822 | 643.74K |
| Oct 21, 2026 | $0.92 | $0.9451 | $0.8786 | $0.895 | 413.54K |
| Oct 20, 2026 | $0.947 | $0.96 | $0.9167 | $0.94 | 469K |
| Oct 19, 2026 | $0.9635 | $0.97 | $0.8999 | $0.9541 | 484.26K |
| Oct 16, 2026 | $1.19 | $1.195 | $1.11 | $1.11 | 212.06K |
| Oct 15, 2026 | $1.20 | $1.22 | $1.19 | $1.19 | 132.85K |
| Oct 14, 2026 | $1.27 | $1.27 | $1.235 | $1.25 | 91.69K |
| Oct 13, 2026 | $1.31 | $1.32 | $1.28 | $1.28 | 58.63K |
| Oct 12, 2026 | $1.35 | $1.35 | $1.30 | $1.31 | 144.48K |
| Oct 9, 2026 | $1.35 | $1.3788 | $1.35 | $1.36 | 36.13K |
| Oct 8, 2026 | $1.38 | $1.385 | $1.33 | $1.35 | 88.04K |
| Oct 7, 2026 | $1.42 | $1.45 | $1.41 | $1.42 | 81.49K |
| Oct 6, 2026 | $1.43 | $1.47 | $1.40 | $1.43 | 132.5K |
| Oct 5, 2026 | $1.37 | $1.465 | $1.36 | $1.41 | 191.98K |
| Oct 2, 2026 | $1.34 | $1.36 | $1.32 | $1.36 | 68.55K |
| Oct 1, 2026 | $1.38 | $1.38 | $1.31 | $1.33 | 120.79K |
Latest NYXH news
The latest Smart Investors Daily articles mentioning NYXH.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NYXH research
Overview
Company profile and research snapshot.
Company profile
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | CANTOR FITZGERALD | Overweight | — |
| Sep 3, 2026 | DEGROOF PETERCAM | Buy | — |
| Aug 17, 2026 | STIFEL EUROPE | Hold | — |
| Aug 6, 2026 | PIPER SANDLER COMPANIES | Overweight | — |
| Aug 6, 2026 | OPPENHEIMER & CO., INC. | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 26, 2026
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026 Mont-Saint-Guibert, Belgium – October 26, 2026, 10:05 pm CET / 5:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the third quarter of 2026 on Thursday, November 5, 2026. Company manage
Yahoo · Oct 22, 2026
Nyxoah (ENXTBR:NYXH) Stock Sees Fair Value Falls After Q2 Analyst Target Cuts
Nyxoah’s consensus fair value has shifted from about €5.80 to roughly €4.40, which is a reduction of close to one quarter in analyst price targets. This reset reflects recent Q2 updates, where some analysts remain encouraged by U.S. commercialization progress, while others are more cautious and prefer to wait for clearer evidence that execution can support earlier expectations. As you read on, you will see how these changing targets shape the evolving Nyxoah story and what signals to watch...
Yahoo · Oct 20, 2026
Here's Why Nyxoah (NYXH) Could be Great Choice for a Bottom Fisher
Nyxoah (NYXH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
